How can an immune response create risks during gene therapy using viral vectors?

In the context of gene therapy, the use of viral vectors to deliver genetic material carries inherent risks related to the body's immune system.

Although viral vectors are modified to remove viral genes and prevent replication, they are still derived from viruses. Consequently, a patient's immune system may recognize the vector as a foreign invader and mount an immune response against it. This reaction can lead to significant safety concerns, as the body's attempt to neutralize the vector may cause inflammation or other adverse health effects, potentially undermining the therapeutic goals of the treatment.12

The history of clinical trials has demonstrated that these immune responses can be severe. For instance, the death of a participant in a 1999 gene therapy trial highlighted the critical nature of these safety challenges. Ensuring patient safety is a fundamental ethical imperative in medical research, and managing the body's reaction to delivery systems remains a primary focus for scientists working to refine these technologies.2